MedTrace Logo

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

NCT02161146 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2019-04-17

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.

Conditions

  • Conjunctivitis, Allergic

Interventions

DRUG

AGN-229666

One drop of AGN-229666 in the eye on Days 1 and 15.

DRUG

Vehicle to AGN-229666

One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.

DRUG

Olopatadine

One drop of olopatadine in the eye on Days 1 and 15.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-04
Primary Completion
2014-12-20
Completion
2014-12-20

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02161146 on ClinicalTrials.gov